

PRESS RELEASE
12 January 2023 08:30:00 CET

Clinical study validates that Stockholm3 provides significantly higher clinical benefit than European prostate cancer risk calculator

A study comparing Stockholm3 with the Rotterdam Prostate Cancer Risk Calculator (RPCRC) has been published in *European Urology Focus* (1). RPCRC is a prostate cancer risk calculator that is recommended in the European Association of Urology guidelines. Stockholm3 showed superior performance and a positive clinical benefit whereas the performance of the RPCRC was suboptimal with a considerable underestimation of prostate cancer risk.

The Rotterdam Prostate Cancer Risk Calculator (RPCRC) and Stockholm3 can both be used to aid urologists in their decision to refer men to magnetic resonance imaging (MRI) or biopsy for early detection of prostate cancer. The objective of the study was to assess the external validity of the RPCRC and compare it with using PSA and Stockholm3 to detect clinically significant prostate cancer. Using data from the prospective, population-based, randomized STHLM3-MRI screening trial, 666 participants were included and the probabilities for clinically significant prostate cancer (csPC) were calculated for each participant using the RPCRC and Stockholm3, with and without prostate volume.

Using RPCRC's recommended risk threshold of ≥ 4 percent for finding csPC, 54 percent of all csPC cases would be detected versus 94 percent using Stockholm3 with a threshold of ≥ 11 percent. Calibration of Stockholm3 was adequate while RPCRC underestimated the risk of csPC. The Stockholm3 test showed positive net benefits at clinically relevant thresholds, while the RPCRC showed negative net benefits. Compared with PSA, the RPCRC was associated with lower detection of csPC (84 vs 103), while Stockholm3 was associated with higher detection of csPC (143 vs 103).

"This study further validates the clinical benefits of Stockholm3 compared to other methods, and a significant potential to improve prostate cancer diagnostics in Europe by finding more cases early, when the patient can be cured. Including Stockholm3 in both guidelines and clinical practice can save substantial costs and free up resources by reducing overdiagnosis. We are already active in Sweden, Norway, Finland, Germany and Switzerland and will target the rest of Europe in our expansion," says David Rosén, CEO of A3P Biomedical.

(1) External Validation of the Rotterdam Prostate Cancer Risk Calculator and Comparison with Stockholm3 for Prostate Cancer Diagnosis in a Swedish Population-based Screening Cohort; Palsdottir et al, *European Urology Focus* 2022.

For additional information, please contact:

David Rosen, CEO
Telephone: +46 10 1823325
Email: david.rosen@a3p.com

About A3P Biomedical

A3P Biomedical's mission is to improve quality of life of men by radically increasing the precision in prostate cancer diagnostics. The company's lead product is **Stockholm3**, a blood test for early detection of aggressive prostate cancer. Stockholm3 has been developed by scientists at Karolinska Institutet and validated in clinical studies including more than 75,000 men. A3P Biomedical is headquartered in Stockholm, Sweden. For more information, please visit www.a3p.com.

About Stockholm3

Stockholm3 is a blood test that combines protein markers, genetic markers, clinical data, and a proprietary algorithm, to predict the risk of aggressive prostate cancer at an early stage. In clinical practice, Stockholm3 finds 100 percent more aggressive prostate cancers and reduces 50 percent of unnecessary biopsies compared to current practice with PSA (2).

Stockholm3 has been evaluated in clinical studies with more than 75,000 men. Data from the latest pivotal study, a randomized study including 12,750 men, was published in The Lancet Oncology in 2021. The study was also awarded the European Association of Urology (EAU) "Prostate Cancer Research Award 2022". Multiple additional studies have been published in high-impact journals, including a previous study with 58,000 men, published in The Lancet Oncology in 2015 (2).

Based on robust peer-reviewed clinical data, leading Nordic healthcare providers such as Capio S:t Görans Hospital in Sweden and Stavanger University Hospital in Norway have replaced PSA with Stockholm3. Region Värmland has introduced general screening for prostate cancer with the help of Stockholm3 for men in the age category 50-75. Patients benefit from a more precise test (increasing sensitivity and specificity) and healthcare providers can reduce the direct costs by 17 to 28 percent (2).

(2) Publications, results and clinical validation.

About prostate cancer

Prostate cancer is the second most common male cancer, and the fifth leading cause of cancer related death in men worldwide. According to WHO, 1.4 million men were diagnosed with prostate cancer and 375,000 deaths were reported in 2020. Incidence of prostate cancer is expected to increase by 70 percent until 2040, driven by an aging population.

Attachments

[Clinical study validates that Stockholm3 provides significantly higher clinical benefit than European prostate cancer risk calculator](#)